Cybin (HELP) Total Non-Current Liabilities (2021 - 2025)

Cybin (HELP) posted quarterly Total Non-Current Liabilities of $28.9 million for Q3 2025, up 294.89% year-on-year from $7.3 million in Q3 2024, and down 35.08% on a QoQ basis from $44.5 million in Q2 2025.

Cybin (HELP) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends

Cybin (HELP) has reported Total Non-Current Liabilities for 5 consecutive years, with $28.9 million the latest figure, recorded in Q3 2025.

  • Quarterly Total Non-Current Liabilities rose 294.89% year-over-year to $28.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.9 million (up 294.89% YoY) and the FY2024 annual result came in at -$11.5 million, changed N/A from the prior year.
  • Total Non-Current Liabilities declined to $28.9 million in Q3 2025 per HELP's latest filing, from $44.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for HELP reached as high as $44.5 million in Q2 2025 and fell as low as -$15.2 million in Q2 2024.
  • A 5-year average of $72554.6 and a median of -$4.1 million in 2021 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 33253.61% — and 2025, when it jumped 392.28%.
  • Year by year, Total Non-Current Liabilities stood at -$4.4 million in 2021, then retreated by 9.02% to -$4.8 million in 2022, then jumped by 100.64% to $30850.5 in 2023, then sank by 33253.61% to -$10.2 million in 2024, then surged by 382.44% to $28.9 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $28.9 million, $44.5 million, and -$10.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Cybin 28.04 Mn 28.04 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 28.89 Mn
Jun 30, 2025 44.50 Mn
Dec 31, 2024 -10.23 Mn
Sep 30, 2024 -14.82 Mn
Jun 30, 2024 -15.23 Mn
Mar 31, 2024 -11.53 Mn
Dec 31, 2023 30,850.49
Sep 30, 2023 -3.78 Mn
Jun 30, 2023 173,457.42
Feb 28, 2023 226,867.54
Dec 31, 2022 -4.79 Mn
Sep 30, 2022 -4.90 Mn
Dec 31, 2021 -4.40 Mn
Sep 30, 2021 -4.47 Mn
Jun 30, 2021 626,415.91
Mar 31, 2021 864,368.44